Reduces LDL-C, Apo B & triglycerides & to increase HDL-C in the treatment of hyperlipidaemias (type IIa or IIb hyperlipoproteinaemias), hypertriglyceridaemia (type IV) & dysbetalipoproteinaemia (type III).
Active liver disease; assess liver function prior to treatment & subsequently when clinically indicated; additional assessment after 3 mth & after dosage increase. Risk of myopathy in patients w/ renal impairment. Discontinue if creatine phosphokinase increases significantly or if myopathy is diagnosed.
Sign Out
